Needham & Company LLC Reaffirms “Buy” Rating for Tempus AI (NASDAQ:TEM)

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 51.37% from the company’s previous close.

A number of other research firms also recently commented on TEM. Morgan Stanley decreased their target price on Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. JPMorgan Chase & Co. reduced their price objective on Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price objective on Tempus AI in a report on Wednesday, February 25th. Finally, HC Wainwright increased their target price on Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Monday. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $78.62.

Tempus AI Stock Down 5.9%

Shares of TEM stock opened at $49.55 on Wednesday. The company’s fifty day simple moving average is $59.45 and its two-hundred day simple moving average is $71.91. Tempus AI has a 52 week low of $36.22 and a 52 week high of $104.32. The stock has a market cap of $8.86 billion, a P/E ratio of -35.14 and a beta of 5.29. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Insider Activity at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 2,902 shares of Tempus AI stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the transaction, the chief accounting officer directly owned 41,159 shares of the company’s stock, valued at $2,430,438.95. The trade was a 6.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO James William Rogers sold 10,084 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $595,460.20. Following the transaction, the chief financial officer owned 101,166 shares in the company, valued at $5,973,852.30. This trade represents a 9.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 570,143 shares of company stock worth $35,595,055 in the last ninety days. Corporate insiders own 26.27% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several institutional investors have recently made changes to their positions in TEM. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in Tempus AI during the 4th quarter valued at about $295,000. Caitong International Asset Management Co. Ltd lifted its stake in Tempus AI by 38,059.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 27,093 shares of the company’s stock worth $1,600,000 after purchasing an additional 27,022 shares during the last quarter. Virtu Financial LLC lifted its stake in Tempus AI by 384.6% in the fourth quarter. Virtu Financial LLC now owns 54,797 shares of the company’s stock worth $3,236,000 after purchasing an additional 43,490 shares during the last quarter. Invesco Ltd. boosted its position in shares of Tempus AI by 21.5% during the fourth quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock valued at $21,947,000 after buying an additional 65,836 shares during the period. Finally, Vident Advisory LLC boosted its position in shares of Tempus AI by 5.3% during the fourth quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock valued at $613,000 after buying an additional 522 shares during the period. Institutional investors own 24.22% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Company releases clinical validation results showing its IPS, PurIST and xF+ diagnostics have stronger evidence for guiding cancer therapy and biomarker detection — a win for commercial adoption and reimbursement potential. Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
• Positive Sentiment: Publication in JCO Precision Oncology (study with The Oncology Institute) shows advanced CGP features (tumor‑normal matched sequencing, RNA metrics, etc.) identify more clinically actionable findings in community oncology — supports Tempus’s test utility and addressable market. Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
• Positive Sentiment: Needham reiterated a Buy and kept a $75 price target, arguing Tempus’s oncology platform and data business are underappreciated with upside from reimbursement and AI-driven growth — a supportive analyst signal for investors. Why Tempus AI Stock Is Up Wednesday?
• Positive Sentiment: Company’s recent earnings call highlighted a clear growth path and operational execution points that underpin revenue and product adoption expectations going forward. Tempus AI Earnings Call Highlights Strong Growth Path
• Neutral Sentiment: Zacks and other outlets republished the clinical‑validation announcement — amplification of the same study helps visibility but adds no new data beyond the primary releases. Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
• Negative Sentiment: Technical/market pressures and company metrics raise short‑term risk: TEM exhibits high volatility (beta ~5.3), elevated debt relative to equity and is trading below its 50‑ and 200‑day moving averages — factors that can amplify downside despite positive fundamental news.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.